68 results match your criteria: "The Royal Marsden Hospital and The Institute of Cancer Research[Affiliation]"

For patients with nonmetastatic soft tissue sarcoma (STS) who are at high risk of local recurrence, the standard of care for limb-conserving local management is combined radiotherapy and surgery. Radiotherapy for STS entails 5 weeks of conventionally fractionated radiotherapy (25 × 2 Gy) preoperatively or 6 or more weeks postoperatively. There is growing interest in the use of preoperative hypofractionated regimes, viz.

View Article and Find Full Text PDF

Background: Prognostic factors are crucial in tailoring treatments for patients with rhabdomyosarcoma (RMS). The European paediatric Soft tissue sarcoma Study Group (EpSSG) and the Children's Oncology Group (COG) employ similar prognostic factors, but utilize them differently resulting in diverse stratification systems. This diversity may result in dissimilar treatment approaches for comparable patients and hinder the comparison of clinical trial results.

View Article and Find Full Text PDF
Article Synopsis
  • A study validated a radiomics model that uses MRI imaging to differentiate between lipomas and atypical lipomatous tumors (ALTs), addressing challenges associated with traditional biopsy methods.
  • Three cohorts were analyzed: two for external validation from the US and UK and one for prospective validation from the Netherlands, utilizing automatic and interactive segmentation methods for tumor imaging.
  • The model demonstrated strong performance with area under the curve (AUC) scores ranging from 0.74 to 0.89, matching or exceeding the diagnostic abilities of expert radiologists.
View Article and Find Full Text PDF

The Impact of Radiation Therapy on Metastatic Rhabdomyosarcoma: Results From the EpSSG MTS 2008 Study.

Int J Radiat Oncol Biol Phys

September 2024

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.

Purpose: Radiation oncologists use radiation variably for children with metastatic rhabdomyosarcoma (RMS). Data from the European paediatric Soft tissue sarcoma Study Group (EpSSG) MTS 2008 study were retrospectively analyzed to validate the previous observation that the use of radiation is associated with improved outcomes and guide future recommendations on radiation use in this patient group.

Methods And Materials: The radiation delivered to 216 patients aged 0 to 21 years with metastatic RMS was retrospectively reviewed and classified as radical (all sites of disease irradiated within the protocol parameters), partial (some sites irradiated within the protocol parameters), and none (no radiation or delivered outside the protocol parameters).

View Article and Find Full Text PDF

Background: The authors report the prospective evaluation of reduced dose alkylator chemotherapy combined with radiotherapy for European Pediatric Soft Tissue Sarcoma Study Group (EpSSG) standard risk nonalveolar rhabdomyosarcoma (NA-RMS).

Patients And Methods: Localized node negative Intergroup Rhabdomyosarcoma Study (IRS) II/III NA-RMS at favorable sites (subgroup C), <25 years old, received five cycles of ifosfamide, vincristine, and dactinomycin (IVA) chemotherapy (30 g/m ifosfamide) and four cycles of vincristine and dactinomycin (if receiving radiotherapy), or nine cycles of IVA (54 g/m ifosfamide) ± radiotherapy. Delayed primary tumor excision was considered for IRS III tumors.

View Article and Find Full Text PDF
Article Synopsis
  • A study investigated the effectiveness of a combination treatment using lenvatinib and pembrolizumab for patients with advanced triple-negative breast cancer (TNBC) who had not responded to previous chemotherapy.
  • In a cohort of 31 patients, the objective response rate was 23% by investigator assessment and 32% by independent review, with higher rates observed in patients with certain biomarkers.
  • Despite some encouraging results, 94% of patients experienced treatment-related adverse events, highlighting the need for careful monitoring in future use of this combination therapy.
View Article and Find Full Text PDF
Article Synopsis
  • A Phase III study tested the efficacy of subcutaneous versus intravenous amivantamab for patients with advanced non-small cell lung cancer (NSCLC) who had progression after prior treatments.
  • Results showed that the subcutaneous form maintained efficacy, with fewer side effects and a significantly longer overall survival, while also being more convenient to administer.
  • Patients receiving subcutaneous amivantamab had less infusion-related reactions and faster administration times, with 85% finding the treatment convenient compared to only 35% in the intravenous group.
View Article and Find Full Text PDF

Background: Extended pleurectomy decortication for complete macroscopic resection for pleural mesothelioma has never been evaluated in a randomised trial. The aim of this study was to compare outcomes after extended pleurectomy decortication plus chemotherapy versus chemotherapy alone.

Methods: MARS 2 was a phase 3, national, multicentre, open-label, parallel two-group, pragmatic, superiority randomised controlled trial conducted in the UK.

View Article and Find Full Text PDF

Active surveillance and emerging medical treatment options for desmoid: when and for whom?

Curr Opin Oncol

July 2024

Department of Medical Oncology, University of Heidelberg, Mannheim University Medical Center, Mannheim Cancer Center (MCC), Sarcoma Unit, Mannheim, Germany.

Article Synopsis
  • This article reviews updated strategies for managing desmoid tumors, highlighting recent research and approaches.
  • Active surveillance has emerged as the main management technique, showing about 50% of cases stabilize or regress without immediate intervention, supported by recent studies with notable progression-free survival rates.
  • Additional randomized trials have investigated medical treatments for more aggressive cases, showing that drugs like sorafenib, pazopanib, and nirogacestat have potential benefits in improving patient outcomes.
View Article and Find Full Text PDF

Purpose: Swallow-related motion of the larynx is most significant in the cranio-caudal directions and of` short duration. Conventional target definition for radical radiation therapy includes coverage of the whole larynx. This study longitudinally examined respiration- and swallow-related laryngeal motions using cine-magnetic resonance imaging.

View Article and Find Full Text PDF

Background: MR-Linac allows for daily online treatment adaptation to the observed geometry of tumor targets and organs at risk (OARs). Manual delineation for head and neck cancer (HNC) patients takes 45-75 minutes, making it unsuitable for online adaptive radiotherapy. This study aims to clinically and dosimetrically validate an in-house developed algorithm which automatically delineates the elective target volume and OARs for HNC patients in under a minute.

View Article and Find Full Text PDF

Unraveling the Myth of Radiation Resistance in Soft Tissue Sarcomas.

Semin Radiat Oncol

April 2024

Department of Radiotherapy, The Leiden University Medical Center, Leiden, The Netherlands; Department of Radiotherapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address:

There is a misconception that sarcomas are resistant to radiotherapy. This manuscript summarizes available (pre-) clinical data on the radiosensitivity of soft tissue sarcomas. Currently, clinical practice guidelines suggest irradiating sarcomas in 1.

View Article and Find Full Text PDF

Background: Epithelioid hemangioendothelioma (EHE) is an ultra-rare, vascular sarcoma with clinical presentation ranging from an indolent to an aggressive form. Over 50% of patients present with metastatic disease, requiring systemic therapy, although no systemic therapies are specifically approved for EHE. Retrospective evidence supports the activity of mTOR inhibitors (e.

View Article and Find Full Text PDF

The Quality Assurance of a 1.5 T MR-Linac.

Semin Radiat Oncol

January 2024

Department of Immunology, Genetics and Pathology, Medical Radiation Physics, Uppsala University, Uppsala, Sweden; Medical Physics, Uppsala University Hospital, Uppsala, Sweden.

The recent introduction of a commercial 1.5 T MR-linac system has considerably improved the image quality of the patient acquired in the treatment unit as well as enabling online adaptive radiation therapy (oART) treatment strategies. Quality Assurance (QA) of this new technology requires new methodology that allows for the high field MR in a linac environment.

View Article and Find Full Text PDF

Background: Real-time dose estimation is a key-prerequisite to enable online intra-fraction treatment adaptation in magnetic resonance (MR)-guided radiotherapy (MRgRT). It is an essential component for the assessment of the dosimetric benefits and risks of online adaptive treatments, such as multi-leaf collimator (MLC)-tracking.

Purpose: We present a proof-of-concept for a software workflow for real-time dose estimation of MR-guided adaptive radiotherapy based on real-time data-streams of the linac delivery parameters and target positions.

View Article and Find Full Text PDF

Introduction: Distended rectums on pre-radiotherapy scans are historically associated with poorer outcomes in patients treated with two-dimensional IGRT. Subsequently, strict rectal tolerances and preparation regimes were implemented. Contemporary IGRT, daily online registration to the prostate, corrects interfraction motion but intrafraction motion remains.

View Article and Find Full Text PDF

Objective: To investigate the feasibility of diffusion-weighted magnetic resonance imaging (DW-MRI) as a predictive imaging marker after neoadjuvant chemotherapy in patients with rhabdomyosarcoma.

Material And Methods: We performed a multicenter retrospective study including pediatric, adolescent and young adult patients with rhabdomyosarcoma, Intergroup Rhabdomyosarcoma Study group III/IV, treated according to the European paediatric Soft tissue sarcoma Study Group (EpSSG) RMS2005 or MTS2008 studies. DW-MRI was performed according to institutional protocols.

View Article and Find Full Text PDF
Article Synopsis
  • A phase Ib study investigated the safety, maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of regorafenib when combined with vincristine and irinotecan for treating kids with relapsed/refractory solid tumors, primarily rhabdomyosarcoma.
  • The study involved 21 patients, determining the MTD/RP2D of regorafenib at 82 mg/m2 when given sequentially; adverse effects mostly included severe blood-related issues, with varying levels of response observed in tumors.
  • Findings suggest that regorafenib can be safely combined with vincristine and irinotecan in pediatric settings, showing promising clinical activity for certain types of tumors.
View Article and Find Full Text PDF
Article Synopsis
  • The study evaluates 2-OHOA, a synthetic lipid, in a Phase 1/2A trial to determine its safety, tolerability, and efficacy for treating gliomas and advanced solid tumors in 54 patients.
  • The trial found that 2-OHOA was well-tolerated at dosage levels, with common side effects being mild gastrointestinal issues, while establishing a recommended phase-2 dose of 12,000 mg daily.
  • Some patients, particularly those with high-grade gliomas, showed promising clinical benefits, with 24% experiencing significant positive responses, including one lasting over 2.5 years.
View Article and Find Full Text PDF

JCO The RMS2005 study included two phase III randomized trials for high-risk (HR) and observational trials for low (LR), standard (SR), and very high-risk (VHR) patients who have been partially reported. Herein, we present a comprehensive report of results achieved for the complete unselected nonmetastatic cohort and analyze the evolution of treatment in comparison with previous European protocols. After a median follow-up of 73.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates whether prior exposure to immune checkpoint inhibitors (ICIs) impacts the severity of COVID-19 in cancer patients, analyzing data from two major registries.
  • Out of 240 cancer patients diagnosed with COVID-19, it was found that vaccination significantly reduced the case fatality rate and related hospitalizations among those who had received ICIs.
  • Additionally, patients who experienced immune-related adverse events (irAEs) prior to COVID-19 had a lower risk of death compared to those without irAEs, suggesting that these events may play a protective role.
View Article and Find Full Text PDF

Background: The prostate demonstrates inter- and intra- fractional changes and thus adaptive radiotherapy would be required to ensure optimal coverage. Daily adaptive radiotherapy for MRI-guided radiotherapy can be both time and resource intensive when structure delineation is completed manually. Contours can be auto-generated on the MR-Linac via a deformable image registration (DIR) based mapping process from the reference image.

View Article and Find Full Text PDF

Background: Brigatinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor with demonstrated efficacy in locally advanced and metastatic non-small cell lung cancer (NSCLC) in crizotinib-refractory and ALK inhibitor-naive settings. This analysis assessed brigatinib in Asian vs. non-Asian patients from the first-line ALTA-1L trial.

View Article and Find Full Text PDF

Background: In ultra-rare sarcomas (URS) the conduction of prospective, randomized trials is challenging. Data from retrospective observational studies (ROS) may represent the best evidence available. ROS implicit limitations led to poor acceptance by the scientific community and regulatory authorities.

View Article and Find Full Text PDF